FDA advisers back Exact Sciences colon cancer test

Published



WASHINGTON (AP) — A panel of Food and Drug Administration advisers has voted to endorse an experimental stool test that uses DNA to detect colon cancer and precancerous growths.

The FDA’s committee of genetic experts voted 10-0 that the benefits of Exact Sciences’ Cologuard test outweigh its risks. The vote amounts to a recommendation for the FDA to approve the test from Exact Sciences of Madison, Wis. The agency is not required to follow the panel’s advice, but often does.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.